Female sex was not associated with a significant difference in 1-year MACE compared to men (9.2% vs 8.1%), but was associated with a higher rate of any BARC bleeding (HR 1.51; 95% CI 1.23-1.85).
Cohort (n=2,047)
Sí
Does female gender impact 1-year ischemic and bleeding outcomes in patients with ACS undergoing PCI and receiving antiplatelet therapy compared to male gender?
In patients with ACS undergoing PCI on antiplatelet therapy, 1-year ischemic outcomes do not differ by gender, but women experience significantly more non-actionable bleeding events.
Tasa de eventos absoluta: 9.2% vs 8.1%
AIMS: Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients. METHODS: In a prospective, observational, multicenter, cohort study, 2047 patients were recruited into the GReekAntiPlatElet (GRAPE) Registry and were followed up until 1 year for major adverse cardiovascular events (MACE, composite of death, nonfatal myocardial infarction, urgent revascularization, and stroke) and bleeding events (Bleeding Academic Research Consortium BARC classification). RESULTS: receptor antagonists) at PCI hospital and at discharge. MACE occurred in 9.2% and 8.1% of women and men, respectively and did not differ significantly by gender. Rate of observed bleeding BARC any type was 57.2% and 44.4% in women and men, respectively. Following adjustment, only differences in BARC any type and BARC type 1 events remained significant, with higher rates observed between women: hazard ratio (95% confidence interval) 1.51 (1.23-1.85) and 1.58 (1.27-1.96), respectively, P<.001 for both. CONCLUSIONS: In a contemporary "real-life" cohort of patients with ACS treated with PCI and focusing on antiplatelet treatment 1-year ischemic outcome does not differ by gender, while women do present more frequently not actionable bleeding events.
Xanthopoulou et al. (Mon,) conducted a cohort in Acute coronary syndrome (n=2,047). Female sex vs. Male sex was evaluated on Major adverse cardiovascular events (composite of death, nonfatal myocardial infarction, urgent revascularization, and stroke). Female sex was not associated with a significant difference in 1-year MACE compared to men (9.2% vs 8.1%), but was associated with a higher rate of any BARC bleeding (HR 1.51; 95% CI 1.23-1.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: